No additional benefit from atropine to stop axial lengthening

Article

No effect when used with orthokeratology lenses for 2 years.

No additional benefit from atropine to stop axial lengthening

Dr Zhi Chen and coauthors from the Department of Ophthalmology and Visual Science, Fudan University Eye Ear Nose and Throat Hospital, Shanghai, China, reported that adding atropine therapy for 2 years in patients who wore orthokeratology lenses did not result in a more positive effect on stopping axial length elongation compared with the use of orthokeratology lenses alone.

The investigators reached this conclusion after a retrospective analysis1 of the axial length status of 73 eyes of 73 patients who wore orthokeratology lenses for 3 years.

During the first year in which the patients wore the lenses, the axial elongation was 0.30 mm or more in all patients.

At this time, the patients were divided into 2 groups; 37 were treated with the lenses and atropine at a dose of 0.01% instilled nightly and 36 continued with the lenses alone. The patients continued with these treatments for 2 years.

The researchers compared the axial elongation over time in both groups.

Comparison of the groups

The authors found that in the group treated with lenses and atropine, the respective mean axial elongation values were0.47 ± 0.15, 0.21 ± 0.15, and 0.23 ± 0.13 mm during years 1, 2, and 3; the respective values in the lens-alone group were 0.41 ± 0.09, 0.30 ± 0.11 and 0.20 ± 0.13 mm.

The cumulative axial elongation over 3 years for both groups were virtually the same and that the overall change in the axial length did not differ significantly (P = 0.262) between the groups.

The researchers also found that the baseline myopic refractive error had a significant (P < 0.001) impact on axial elongation over the 3 years. The baseline parameters, age, lens design and treatment did not significantly impact the axial length elongation.

The authors concluded that atropine 0.01% instillation in patients with rapid progression of myopia and poor responders to orthokeratology lens use did not significantly change the 3-year axial elongation outcome when compared with use of orthokeratology lenses alone.

Reference
1. Chen Z, Zhou J, Xue F, Qu X, Zhou X. Two-year add-on effect of using low concentration atropine in poor responders of orthokeratology in myopic children. Br J Ophthalmol. Published online July 21, 2022; http://dx.doi.org/10.1136/bjophthalmol-2020-317980

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.